For gene editing to achieve its potential, companies must solve an economic problem, not just a scientific one. The key is developing a manufacturing system that dramatically lowers costs, making one-time cures for the "long tail" of rare mutations financially viable and accessible.

A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

The tech world is fixated on trivial AI uses while monumental breakthroughs in healthcare go underappreciated. Innovations like CRISPR and GLP-1s can solve systemic problems like chronic disease and rising healthcare costs, offering far greater societal ROI and impact on longevity than current AI chatbots.

George Church bypasses the typical ethical debate, arguing germline editing faces three key business challenges: it doesn't apply to the 8 billion people already alive, clinical trials for late-onset diseases would take 80+ years, and it lacks a clear application not solvable by other means.

Gene editing pioneer David Liu is developing a platform that could treat multiple, unrelated genetic diseases with a single therapeutic. By editing tRNAs to overcome common nonsense mutations, one therapy could address a wide range of conditions, dramatically increasing scalability and reducing costs.

George Church predicts that reversing aging via somatic gene therapy will be the first truly mainstream genetic enhancement. Since aging will affect 90% of the population, therapies that restore youthful function in the elderly will have a massive impact and widespread adoption, becoming the "GLP-1 moment" for gene editing.

The field was stalled by the risk of transmitting porcine retroviruses to humans. The problem was intractable because 50-70 viral copies are spread across the pig genome. CRISPR's unique ability to efficiently make that many edits was the specific breakthrough needed to mitigate this key safety risk.

George Church envisions a future where, in emergencies, millions of barcoded gene therapies could be tested simultaneously in one patient. This approach combines high-throughput synthesis with in-vivo testing to achieve nearly 100% accuracy by using a real human biological system.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.